Modality
Gene Editing
MOA
BCMA ADC
Target
SOS1
Pathway
Fibrosis
CF
Development Pipeline
Preclinical
~Nov 2012
→ ~Feb 2014
Phase 1
~May 2014
→ ~Aug 2015
Phase 2
~Nov 2015
→ ~Feb 2017
Phase 3
May 2017
→ Aug 2029
Phase 3Current
NCT03668024
1,511 pts·CF
2020-09→2027-12·Completed
NCT04108994
1,116 pts·CF
2017-05→2029-08·Recruiting
2,627 total pts1 indication
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (2)
2027-12-281.7y awayPh3 Readout· CF
2029-08-093.4y awayPh3 Readout· CF
Trial Timeline
Q2Q3Q42018Q2Q3Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q4
P3
Recruit…
P3
Complet…
Catalysts
Ph3 Readout
2027-12-28 · 1.7y away
CF
Ph3 Readout
2029-08-09 · 3.4y away
CF
RecruitingCompleted|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT03668024 | Phase 3 | CF | Completed | 1511 | SRI-4 |
| NCT04108994 | Phase 3 | CF | Recruiting | 1116 | FEV1 |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Terarelsin | AbbVie | Preclinical | SOS1 | |
| AZN-3724 | AstraZeneca | Preclinical | PSMA | |
| Ribofutibatinib | AstraZeneca | Phase 2/3 | SOS1 | |
| Olpatinib | GSK | Preclinical | PD-L1 | |
| GIL-9779 | Gilead Sciences | Phase 1 | IL-17A | |
| Voxacagene | Gilead Sciences | Phase 2/3 | SOS1 | |
| SRP-9822 | Sarepta | Phase 3 | SOS1 | |
| Sematenlimab | Samsung Biologics | Phase 3 | PI3Kα | |
| Fixaosocimab | TG Therapeutics | Phase 2/3 | SOS1 | |
| Zanurapivir | Immunocore | Phase 1 | SOS1 |